EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency

Marta Santiago, Alessandro Liquori iD, Esperanza Such, Ángel Zúñiga, José Cervera iD

Cancers · 03.03.2023 · 15 (5) · 1590

DOI: 10.3390/cancers15051590 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 03.03.2023. Verfasst von Marta Santiago und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital La Fe, 46026 Valencia, Spain. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Federación Española de Enfermedades Raras, Instituto de Salud Carlos III, Fundació La Marató de TV3.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hereditary myeloid malignancy syndromes (HMMSs) are rare but are becoming increasingly significant in clinical practice. One of the most well-known syndromes within this group is GATA2 deficiency. The GATA2 gene encodes a zinc finger transcription factor essential for normal hematopoiesis. Insufficient expression and function of this gene as a result of germinal mutations underlie distinct clinical presentations, including childhood myelodysplastic syndrome and acute myeloid leukemia, in which the acquisition of additional molecular somatic abnormalities can lead to variable outcomes. The only curative treatment for this syndrome is allogeneic hematopoietic stem cell transplantation, which should be performed before irreversible organ damage happens. In this review, we will examine the structural characteristics of the GATA2 gene, its physiological and pathological functions, how GATA2 genetic mutations contribute to myeloid neoplasms, and other potential clinical manifestations. Finally, we will provide an overview of current therapeutic options, including recent transplantation strategies.

Schlagwörter

Stichwörter der Autor:innen

GATA2 deficiencyGATA2 haploinsufficiencygermline mutationpredisposition to myeloid neoplasms

Autor:innen und Institutionen

  • Hematology Department, Hospital La Fe, 46026 Valencia, Spain.
  • Hematology Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
  • Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
  • Genetics Unit, Hospital La Fe, 46026 Valencia, Spain.

ORCID-Profile: Alessandro Liquori, José Cervera

Förderung

  • Federación Española de Enfermedades Raras
  • Instituto de Salud Carlos III
  • Fundació La Marató de TV3
  • Generalitat Valenciana
  • Asociación Española Contra el Cáncer
  • FEDER
  • Conselleria de Educación, Cultura y Deporte
  • Rio Hortega

Zitieren

APA

Santiago, M., Liquori, A., Such, E., Zúñiga, Á., & Cervera, J. (2023). The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency. Cancers, 15(5), 1590. https://doi.org/10.3390/cancers15051590

Vancouver

Santiago M, Liquori A, Such E, Zúñiga Á, Cervera J. The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency. Cancers. 2023;15(5):1590. doi:10.3390/cancers15051590

BibTeX
@article{Santiago2023,
  author = {Santiago, Marta and Liquori, Alessandro and Such, Esperanza and Zúñiga, Ángel and Cervera, José},
  title = {The Clinical Spectrum, Diagnosis, and Management of GATA2 Deficiency},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1590},
  doi = {10.3390/cancers15051590}
}
Kostenlos starten →